Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
Go back to Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting| (NASDAQ: XENE) | Delayed: 54.61 -0.18 (0.33%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $54.79 | 52 Week High | $9.75 | |||
| Open | $54.62 | 52 Week Low | $5.65 | |||
| Day High | $55.47 | P/E | N/A | |||
| Day Low | $54.12 | EPS | $0.00 | |||
| Volume | 1,498,297 | |||||
